Navigation Links
YM BioSciences reports second quarter 2010 operational and financial results
Date:2/8/2010

the products from merging the Australian company, Cytopia Limited, into YM, which occurred January 29, 2010, the Company is currently developing four late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM); a CYT 387 JAK 1/2 small molecule inhibitor, CYT 997, a potent, vascular disrupting agent and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is importantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. In more than 9,000 patients reported as having been treated with nimotuzumab worldwide to date, Grade IV incidents of radiation dermatitis and incidents of severe rash have been only rarely observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been equally rare. Nimotuzumab is licensed to YM's majority-owned, Canadian subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. Cytopia has two products in clinical development. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 by Dr. Andrew Wilks, the founder of Cytopia. The orally active vascular disrupting agent, CYT997, also arose from this early research. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using opioids
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
2. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
3. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
4. Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
5. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
6. YM BioSciences announces result of Cytopia shareholder vote
7. Profectus Biosciences to Present at Key Investor Conference in January 2010
8. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
9. YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract
10. Nu-Tek BioSciences, LLC. Launches Animal-Free, Non-GM Soy Peptone
11. Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Research and Markets has ... Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on ... The report provides a basic overview ... industry chain structure. The N-acetylcysteine market analysis is ...
(Date:9/18/2014)... , Sept. 18, 2014  U.S. biotech company ... signing an exclusive license for technology developed by the ... gene expression in plants, including for applications in production ... The technology was developed under the direction ... at Kultevat and former president of the Danforth Plant ...
(Date:9/18/2014)... , Pennsylvanie, 18 septembre 2014 /PRNewswire/ ... en 1974, a été depuis ... compléter les évaluations cliniques traditionnelles par des ... Outcomes) et sur les impacts économiques des ... A cours d,une ...
(Date:9/18/2014)... rare diseases that afflict skeletal growth through abnormalities ... the fetal stage and is caused by genetic ... growth factor receptor 3 (FGFR3) has been associated ... (TD), a skeletal dysplasia that cause serious respiratory ... achondroplasia (ACH), which causes stunted growth and other ...
Breaking Biology Technology:Global N-acetylcysteine Industry Report 2014 2Kultevat obtains license of gene switch technology 21974 - 2014 - Mapi fĂȘte ses 40 ans 2Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3
... Directors,of Eli Lilly and Company (NYSE: LLY ) ... December 1, 2008. Oberhelman, 55, currently serves as,a group ... Caterpillar,s,executive office. As a member of Lilly,s board, Oberhelman ... committee. He will stand for,election by Lilly shareholders at ...
... KANNAPOLIS, N.C., Oct. 20 Academia, science, industry,and ... at 10,AM at the Dedication and Open House ... the UNC Nutrition Research Building and the NC,State ... Nutrition,Research Building is home to NC A&T University, ...
... Recruitment, and Employment Branding joins Pierpoint International as Global VP of ... ... (PRWEB) October 20, 2008 -- Pierpoint International is pleased to announce ... and Diversity. Mr. Cantu, most recently served as AVP of Staffing ...
Cached Biology Technology:Douglas Oberhelman Elected to Lilly Board of Directors 2Douglas Oberhelman Elected to Lilly Board of Directors 3Campus Celebrates Historic Milestone 2Campus Celebrates Historic Milestone 3Campus Celebrates Historic Milestone 4Campus Celebrates Historic Milestone 5Robert Cantu Appointed Vice President of Pierpoint International 2
(Date:9/19/2014)... A new study shows that legume plants regulate ... cytokininssignaling molecules that are transmitted through the plant ... the number of bacteria-holding nodules in the roots. ... the National Institute for Basic Biology, the Graduate ... Center for Sustainable Resource Science in Japan. ...
(Date:9/18/2014)... Colo., USA Miranda, a small, icy moon of ... enigmatic bodies in the solar system. Despite its relatively ... of intense resurfacing that resulted in the formation of ... polygonal-shaped regions called coronae. , These coronae are ... at least 200 km across. Arden corona, the largest, ...
(Date:9/18/2014)... "frequent flyers" program, fruit flies surely would be eligible ... increasing numbers of fruit fly research studies. One fruit ... and another is scheduled launch to the station Sept. ... December. , Fruit flies are biomedical research models studied ... organisms can reveal the basis for health and disease ...
Breaking Biology News(10 mins):For legume plants, a new route from shoot to root 2Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4
... MIAMI March 10, 2011 -- Scientists from the University ... were part of a national research team to find two ... Horizon oil spill. In a study published in this week,s ... offers new insight into the mechanism by which the crude ...
... of California, San Francisco (UCSF) has developed a new ... but untreatable and incurable neurodegenerative disease. The disease, frontotemporal ... dementia before age 65, after Alzheimer,s disease. Based ... work explains in part why the brain deteriorates in ...
... New Orleans, LA LSU oncologist Vince D. ... article reporting two chemotherapy drugs now indicated for second ... cancer are remarkably effective in treating a certain subset ... of Medicine at LSU Health Sciences Center New Orleans ...
Cached Biology News:New study reveals aerosol plumes downwind of the Deepwater Horizon oil spill 2UCSF report describes new model for neurodegeneration 2UCSF report describes new model for neurodegeneration 3Study shows new treatment strategy effective for certain lung cancers 2
Peptide-affinity Purified Polyclonal Antibody to Olfactory Receptor, Family 2, Subfamily H, Member 3...
... collects data from balances and scales with RS232 ... other program. If you can type the weight ... collection process Simple to use parser extracts ... , Add user information , Collect data at ...
... collection and automation that is controlled from within ... , Pre-configured library of interfaces for balances, ... be added and configured by the user ... one spreadsheet , Allows for multi-tasking ...
...
Biology Products: